XLO
Xilio Therapeutics, Inc. · Healthcare
Insiders bought $44K of Xilio Therapeutics, Inc. in the last 12 months
1 insider bought on 1 day.
XLO over the last year
Largest buyers, last 12 months
XLO after insider buys
3 months after each buy, from the first price a copier could get.
4 buys since 2021 with 3 months of prices.
Every filing
10 insider filings since 2021, newest first
James Samuel Shannon · Director
James Samuel Shannon · Director
Gilead Sciences, Inc. · 10% owner
Gilead Sciences, Inc. · 10% owner
Sv7 Impact Medicine Fund LP · 10% owner
James E Flynn · Possible Member of 10% Group, 10%
Rivervest Venture Fund Iv, L.P. · 10% owner
Rock Springs Capital Management LP · 10% owner
Bay City Capital LLC · 10% owner
Atlas Venture Fund Xi, L.P. · 10% owner
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.